Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2

Status

Recruiting 3Active not recruiting 1

Sponsor Class

NETWORK 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Multiple Myeloma 120Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Recurrence 17Burkitt Lymphoma 15Lymphoma, Large B-Cell, Diffuse 8Neoplasms, Plasma Cell 7Immunoglobulin Light-chain Amyloidosis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Leukemia, Biphenotypic, Acute 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Leukemia 4Waldenstrom Macroglobulinemia 3Nausea 3Lymphoma, B-Cell 3Brain Neoplasms 3Smoldering Multiple Myeloma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Down Syndrome 2

Interventions

Specimen Handling 54Carboplatin 51pembrolizumab 50Magnetic Resonance Spectroscopy 46Pemetrexed 41Cisplatin 36durvalumab 26Paclitaxel 25Nivolumab 23osimertinib 22Radiosurgery 20Gemcitabine 20Radiotherapy 17Docetaxel 17Immunoglobulin G 15Biopsy 15atezolizumab 14Disulfides 14130-nm albumin-bound paclitaxel 13Taxes 12Radiation 11Etoposide 11Educational Status 11Blood Specimen Collection 11Drug Therapy 10X-Rays 9Platinum 9Early Intervention, Educational 9Practice Guidelines as Topic 8Methods 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lung Neoplasms × Dexamethasone × 90 days × Clear all
NCT06788912 2026-05-26

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05986318 2026-03-09

RESPIRE-ILD

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Recruiting
98 enrolled
Thoracic

Lung Neoplasms, Lung Diseases, Interstitial, Radiation Pneumonitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡